Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

Background: Previous trials suggest no differences in immunotherapy treatment between older and younger patients, but mainly young patients with a good performance status were included. The aim of this study was to describe the treatment patterns and outcomes of “real-world” older patients with meta...

Full description

Bibliographic Details
Main Authors: Nienke A. de Glas, Esther Bastiaannet, Frederiek van den Bos, Simon P. Mooijaart, Astrid A. M. van der Veldt, Karlijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan-Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Hilde Jalving, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Gerard Vreugdenhil, Michel W. J. M. Wouters, Johanneke E. A. Portielje, Ellen W. Kapiteijn
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
immunotherapy
melanoma
older adults
geriatric oncology
toxicity
response
Online Access:https://www.mdpi.com/2072-6694/13/11/2826

Internet

https://www.mdpi.com/2072-6694/13/11/2826

Similar Items